Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alnylam Pharmaceuticals Inc ALNY

Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for... see more

Recent & Breaking News (NDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ALNY

Accesswire April 11, 2024

ALNY STOCK ALERT: Levi & Korsinsky Notifies Alnylam Pharmaceuticals, Inc. Investors of an Ongoing Investigation

Accesswire April 10, 2024

Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ALNY

Accesswire April 9, 2024

Did Alnylam Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ALNY

Accesswire April 8, 2024

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Business Wire April 7, 2024

Levi & Korsinsky Announces an Investigation on Behalf of Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who May Have Been Affected by Fraud

Accesswire March 29, 2024

Investors who lost money on Alnylam Pharmaceuticals, Inc. should contact Levi & Korsinsky about an ongoing investigation - ALNY

Accesswire March 28, 2024

Alnylam Being Investigated on Behalf of Alnylam Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.

Accesswire March 26, 2024

Lost Money on Alnylam Pharmaceuticals, Inc.(ALNY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

Accesswire March 25, 2024

Alnylam Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- ALNY

Accesswire March 22, 2024

Did Alnylam Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- ALNY

Accesswire March 21, 2024

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session

Business Wire March 20, 2024

ALNY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Alnylam Pharmaceuticals, Inc. Investment

Accesswire March 20, 2024

ALNY STOCK ALERT: Levi & Korsinsky Notifies Alnylam Pharmaceuticals, Inc. Investors of an Ongoing Investigation

Accesswire March 19, 2024

Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ALNY

Accesswire March 14, 2024

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease

Business Wire March 13, 2024

ALNY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Alnylam Pharmaceuticals, Inc.

Accesswire March 13, 2024

Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates

Accesswire March 11, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

PR Newswire March 11, 2024

Levi & Korsinsky Announces an Investigation on Behalf of Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who May Have Been Affected by Fraud

Accesswire March 11, 2024